Heme Workshop Banner 2022
SIGN IN

Hematologic Malignancies Workshop Agenda

Meeting Objectives

  • Evaluate recent clinical trial data focused on the safety and efficacy of novel therapeutic agents and combination strategies that target the tumor microenvironment in hematologic malignancies
  • Describe the impact of large-scale immune profiling efforts on the development of novel therapeutic targets
  • Explore how emerging pathways and strategies targeting the immune microenvironment are used to inform and optimize precision medicine
  • Gain insights on the role of the tumor microenvironment in solid tumors and evaluate appropriate agents that promote tumor regression
  • Foster collaboration between academic and industry researchers to evaluate novel therapeutic approaches in hematologic malignancies

Agenda is subject to change

Thursday, September 22

Duration
Topic
3:00 PM – 3:05 PM
Welcome and Introductions
3:05 PM – 3:20 PM
Presentation: Translational Workshop on Hematologic Malignancies – Lessons Learned Over the Last 10 Years
Kieron Dunleavy, MD (Georgetown University)
3:20 PM – 3:50 PM
Keynote: Impact of the Microenvironment on CAR T-cells
3:50 PM – 4:05 PM
Presentation: The Role of the Microenvironment in Tumor Progression and Treatment Outcomes
Kenneth Anderson, MD (Dana-Farber Cancer Institute)
4:05 PM – 4:25 PM
Breakout Session: Large-Scale Immune Profiling in Hematologic Malignancies
  • Microenvironment and Epigenetic Regulation in Lymphoma
  • Industry Perspectives
4:25 PM – 5:10 PM
Summary of Discussion to Large Group
5:10 PM – 5:25 PM
Presentation:Barriers in Eradicating Extramedullary B-ALL with CAR T-cell therapy Nirali Shah, MD (National Cancer Institute)
5:25 PM – 5:40 PM
Presentation: Role of Non-coding Mutations Targeting Super-Enhancers in Lymphoma
Laura Pasqualucci, MD (Columbia University)
5:40 PM – 5:45 PM
Wrap Up and Adjourn
7:00 PM – 10:00 PM
Welcome Dinner

Friday, September 23

Duration
Topic
8:30 AM – 9:00 AM
Breakfast
9:00 AM – 9:15 AM
Presentation: Emerging Concepts in Immune Regulation and Targeting in Lymphoma
David Maloney, MD, PhD (Fred Hutchinson Cancer Research Center)
9:15 AM – 9:30 AM
Presentation: Waldenstrom’s Macroglobulinemia
9:30 AM – 9:50 AM
Breakout Session: Recent Advances in Characterizing the Microenvironment in Lymphoma
  • Treatment Options for Patients with Richter’s Transformation
  • Review of Current Clinical Trial Data of CAR T, BTKi, and Bispecifics
  • Sequencing Immunotherapy and Novel Combination Strategies
  • Industry Perspectives
9:50 AM – 10:35 AM
Summary of Discussion to Large Group
Moderated by Loretta Nastoupil, MD (MD Anderson Cancer Center)
10:35 AM – 10:55 AM
Industry Presentation
10:55 AM – 11:10 AM
Coffee Break
11:10 AM – 11:25 AM
Presentation: Novel Therapeutic Strategies That Utilize the Microenvironment to Improve Outcomes in Leukemia
Jan Burger, MD, PhD (MD Anderson Cancer Center)
11:25 AM – 11:45 AM
Breakout Session & Discussion: Current Advances Targeting Immunity and the Microenvironment in Leukemia
  • BTK Inhibitors in CLL
  • Role of the Microenvironment in Resistance to Therapy in AML
  • Industry Perspectives
11:45 AM – 12:30 PM
Summary of Discussion to Large Group
12:30 PM – 1:30 PM
Lunch
1:30 PM – 2:00 PM
Pathogenesis of LGL Leukemia
Tom Loughran, MD (University of Virginia)
2:00 PM – 2:15 PM
Presentation: New Approaches for CAR T-cell Therapy in Hematologic Malignancies
(bi-specific antibodies, targeting ALL/CD-22/CD-19) Jennifer Brudno, MD (National Cancer Institute)
12:30 PM – 1:30 PM
Lunch
1:30 PM – 1:45 PM
Presentation: Tumor Microenvironment and Targeting Strategies in an Era of Precision Medicine
Presenter TBC
2:15 PM – 2:35 PM
Breakout Session: Unifying Immune Therapy with Precision Medicine
  • Incorporating ctDNA into Clinical Practice
  • Interplay of Genomics with the Tumor Microenvironment
  • Industry Perspectives
2:35 PM – 3:20 PM
Summary of Discussion to Large Group
Catherine Bollard, MD, MBChB (Children’s National Hospital)
3:20 PM – 3:35 PM
Coffee Break
3:35 PM – 3:50 PM
Industry Presentation
3:50 PM – 4:05 PM
Immune Microenvironment in Solid Tumors
Chrystal Paulos, PhD (Emory University)
4:05 PM – 4:20 PM
FDA Presentation
Bindu Kanapuru, MD (Food and Drug Administration/CDER/OHOP)
3:30 PM – 4:00 PM
Pathogenesis of LGL Leukemia
Tom Loughran, MD (University of Virginia)
4:20 PM – 5:00 PM
Reception: Poster Display and Discussion
7:00 PM – 9:00 PM
Dinner

Saturday, September 24

Duration
Topic
8:30 AM – 9:00 AM
Breakfast
9:00 AM – 9:15 AM
Presentation: Insights into the Immune Microenvironment in Multiple Myeloma
Madhav Dhodapkar, MBBS (Emory University)
9:15 AM – 9:35 AM
Breakout Session: Targeting the Tumor Microenvironment in Multiple Myeloma
  • Impact of the Immune Microenvironment on CAR T Treatment, Proteasome Inhibitors, Anti-CD38 Monoclonal Antibodies, ADCs, CELMoDs, and IMiDs
  • Sequencing Immunotherapy and Novel Combination Strategies
  • Industry Perspectives
9:35 AM – 10:20 AM
Summary of Discussion to Large Group
Moderated by Sagar Lonial, MD, FACP (Emory University)

10:20 AM – 10:50 AM

Keynote: Immune Microenvironment and Cell medicine
Helen Heslop, MD, DSc (Baylor College of Medicine)
10:50 AM – 11:50 AM
Working Session
  • Interactive, open discussion to develop an article or other output that recaps the key findings from the meeting
11:50 AM – 12:00 PM
Closing Remarks, Action Items for 2023, and Adjourn
Sagar Lonial, MD, FACP (Emory University)

Thursday, September 22

Duration

Topic

3:00 PM – 3:05 PM
Welcome and Introductions
3:05 PM – 3:20 PM
Presentation: Translational Workshop on Hematologic Malignancies – Lessons Learned Over the Last 10 Years Kieron Dunleavy, MD (Georgetown University)
3:20 PM – 3:50 PM
Keynote: Impact of the Microenvironment on CAR T-cells Presenter TBC
3:50 PM – 4:05 PM
Presentation: The Role of the Microenvironment in Tumor Progression and Treatment Outcomes Kenneth Anderson, MD (Dana-Farber Cancer Institute)
4:05 PM – 5:10 PM
Breakout Session & Discussion: Large-Scale Immune Profiling in Hematologic Malignancies
  • Microenvironment and Epigenetic Regulation in Lymphoma
  • Industry Perspectives
4:25 PM – 5:10 PM
Summary of Breakouts/Large Group Discussion
5:10 PM – 5:25 PM
Immune Microenvironment in Solid Tumors Chrystal Paulos, PhD (Emory University)
5:25 PM – 5:40 PM
Panel Discussion and Q&A
5:40 PM – 5:45 PM
Wrap Up and Adjourn
7:00 PM – 10:00 PM
Welcome Dinner

Friday, September 23

Duration
Topic
8:30 AM – 9:00 AM
Breakfast
9:00 AM – 9:15 AM
Presentation: Emerging Concepts in Immune Regulation and Targeting in Lymphoma David Maloney, MD, PhD (Fred Hutchinson Cancer Research Center)
9:15 AM – 10:20 AM
Breakout Session & Discussion: Recent Advances in Characterizing the Microenvironment in Lymphoma
  • Treatment Options for Patients with Richter’s Transformation
  • Review of Current Clinical Trial Data of CAR T, BTKi, and Bispecifics
  • Sequencing Immunotherapy and Novel Combination Strategies
  • Industry Perspectives
9:35 AM – 10:20 AM
Summary of Breakouts/Large Group Discussion
10:20 AM – 10:40 AM
Industry Presentation
10:40 AM – 10:55 AM
Coffee Break
10:55 AM – 11:10 AM
Presentation: Novel Therapeutic Strategies That Utilize the Microenvironment to Improve Outcomes in Leukemia Jan Burger, MD, PhD (MD Anderson Cancer Center)
11:10 AM – 12:15 PM
Breakout Session & Discussion: Current Advances Targeting Immunity and the Microenvironment in Leukemia
  • BTK Inhibitors in CLL
  • Role of the Microenvironment in Resistance to Therapy in AML
  • Industry Perspectives
11:30AM – 12:15 PM
Summary of Breakouts/Large Group Discussion
12:15 PM – 12:30 PM
Presentation: New Approaches for CAR T-cell Therapy in Hematologic Malignancies (bi-specific antibodies, targeting ALL/CD-22/CD-19) Jennifer Brudno, MD (National Cancer Institute)
12:30 PM – 1:30 PM
Lunch
1:30 PM – 1:45 PM
Presentation: Tumor Microenvironment and Targeting Strategies in an Era of Precision Medicine Presenter TBC
1:45 PM – 2:50 PM
Breakout Session & Discussion: Unifying Immune Therapy with Precision Medicine
  • Incorporating ctDNA into Clinical Practice
  • Interplay of Genomics with the Tumor Microenvironment
  • Industry Perspectives
2:05 PM – 2:50 PM
Summary of Breakouts/Large Group Discussion
2:50 PM – 3:00 PM
Coffee Break
3:00 PM – 3:15 PM
Industry Presentation
3:15 PM – 3:30 PM
FDA Presentation Bindu Kanapuru, MD (Food and Drug Administration/CDER/OHOP)
3:30 PM – 4:00 PM
Pathogenesis of LGL Leukemia Tom Loughran, MD (University of Virginia)
4:00 PM – 5:00 PM
Poster Display and Discussion Session
7:00 PM – 9:00 PM
Dinner Reception

Saturday, September 24

Duration
Topic
8:30 AM – 9:00 AM
Breakfast
9:00 AM – 9:15 AM
Presentation: Insights into the Immune Microenvironment in Multiple Myeloma Madhav Dhodapkar, MBBS (Emory University)
9:15 AM – 10:20 AM
Breakout Session & Discussion: Targeting the Tumor Microenvironment in Multiple Myeloma
  • Impact of the Immune Microenvironment on CAR T Treatment, Proteasome Inhibitors, Anti-CD38 Monoclonal Antibodies, ADCs, CELMoDs, and IMiDs
  • Sequencing Immunotherapy and Novel Combination Strategies
  • Industry Perspectives
9:35 PM – 10:20 AM
Summary of Breakouts/Large Group Discussion
10:20 AM – 10:50 AM
Keynote: Immune Microenvironment and Cell medicine Helen Heslop, MD, DSc (Baylor College of Medicine)
10:50 AM – 11:50 AM
Working Session
  • Interactive, open discussion to develop an article or other output that recaps the key findings from the meeting

11:50 AM – 12:00 PM

Closing Remarks, Action Items for 2023, and Adjourn Sagar Lonial, MD, FACP (Emory University)